Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 May 2011: Clinical Research  

Prognostic value of duration of untreated psychosis in long-term outcome of schizophrenia

Andrzej Cechnicki ABCDEFG , Igor Hanuszkiewicz DE , Romuald Polczyk CD , Anna Bielańska DEF

DOI: 10.12659/MSM.881768

Med Sci Monit 2011; 17(5): CR277-283

0 Comments

Background

OBJECTIVES OF THE STUDY:

Research commenced during the patient’s first psychiatric admission, and the follow-up periods were 1, 3, 7 and 12 years after the index hospitalisation. This study was part of the Cracovian Prospective Study on the Course of Schizophrenia, which was conducted in real time, meaning that it relies on long-term observation of patients with schizophrenia, starting with the first episode and continuing throughout all years of living with the illness, and involving assessment of treatment outcomes and the efficiency of psychosocial intervention, as well as the role of prognostic factors. The purpose of this study was to determine whether the dynamics of long-term treatment outcomes in the 12-year follow-up (1997–2000) in patients suffering from schizophrenia are dependent on the duration of untreated psychosis (DUP). The indicators of treatment outcomes were: number of relapses, duration and number of inpatient readmissions, and intensity of psychopathological symptoms at subsequent follow-up assessments.

STUDY GROUP:

From among 80 patients with schizophrenia and diagnosed according to DSM III, which diagnosis was later confirmed with DSM IV – TR [22], the analysis included 58 patients who were assessed at all the aforementioned follow-up points, that is, 77% of the original study group. At the onset of the illness, the average age was 27.32 years (OS=6.20; range 18 to 44). Table 1 presents the prognostic demographic, social and illness-related factors that characterised the study group at the first psychiatric admission.

Material and Methods

The prodromal demographic and social factors were assessed with the use of a modified version of the Carpenter-Strauss prognostic scale. To evaluate expressed emotions, the semi-structured Camberwell Family Interview (CFI) was applied. Intensity of symptoms was measured with the UCLA-modified BPRS-LA scale. The follow-up data were gathered at subsequent intervals (1, 3, 7, and 12 years after the first psychiatric admission) with the use of the Alanen and Räkköläinen follow-up interview [15,19]. The analysis embraced the following independent variables:

The following indicators of treatment outcome (ie, dependent variables) were selected:

The independent variables formed a 2-factor research plan with 1 between-group factor (DUP) and 1 repeated measurement factor. The research plan took the form 2×3 in the case of number and duration of readmissions; 2×4 in the case of number of relapses; and 2×5 in the case of BPRS).

Analysis of variance (ANOVA) was used to analyze the results. The main effects of the dynamics and interactions between the factor of repeated measurement and the DUP were calculated. Whenever significant correlations were obtained, simple effects were calculated as well. The objective of the interaction analysis was to find out if the dynamic of change in 1 parameter is dependent on the DUP. In other words, the question under investigation was whether this dynamic is different for patients with a long DUP vs. patients with a short DUP. The significance of differences between the groups with long and short DUP at subsequent follow-up points was evaluated by means of simple effects analysis.

Results

The first series of analyses assessed the dynamics of numbers of relapses, numbers of readmissions, duration of readmissions and intensity of symptoms assessed using the BPRS, as well as the interaction between this dynamic and the DUP. The analysis of variance results are presented in Table 2.

The analysis of variance showed that for all 3 dependent variables (number of relapses, number of readmissions, and duration of readmissions), the dynamic was statistically significant. At subsequent follow-up points, the results were higher for all the variables. This effect is illustrated by Figures 1A and B.

The dynamics of the number of relapses was not identical in the groups with long and short DUP (p<0.001). The increase in the number of relapses at subsequent follow-up points was higher in the group with the long DUP (Figure 2).

The analyses of simple effects demonstrated that the groups with long and short DUP did not differ significantly (with p equalling 0.937 and 0.794, respectively) at 1-year and 3-year follow-up. The difference became significant at the 7-year follow-up (p=0.036), but not at the 12-year follow-up (p=0.154). It may be assumed that the reason for this was the relatively high standard error at this point of measurement.

A marginally significant interaction was observed concerning duration of readmissions, between its dynamic and the DUP (p=0.051). This is shown in Figure 3.

Interpretation of this interaction is complicated by the fact that no simple effects related to the comparison of the groups with short and long DUP at particular follow-up points provided any statistically significant findings (p amounted to: 0.43, 0.41 and 0.31, respectively). It may thus be conservatively stated that the dynamics of duration of readmissions seem to be stronger (increase more sharply) in the group with the longer DUP.

The second set of analyses addressed the BPRS-LA scale. It included 5 measurement points: index hospitalization, discharge, and 3-, 7- and 12-year follow-ups. As before, the dynamics of change at particular points were first investigated overall, and then in relation to the short and long DUP. The results of the analysis of variance (ANOVA) in relation to the dynamics of the general BPRS assessment and the interaction with DUP are presented in Table 3.

The results shown in Table 3 show that the dynamic was statistically significant for all the 3 indices of the BPRS. Figure 4 shows that all parameters decreased with time. The most noticeable decrease of the investigated parameters occurred between index hospitalization and discharge. Subsequently, between discharge and the 12-year follow-up, the changes were slight. This observation, however, refers to the analysis that does not take into account the impact of the DUP.

When that impact was considered, a number of interesting interactions emerged. Overall BPRS results were lower (i.e., improvement was noticed in symptomatology) in the patients characterised by short DUP (Figure 5). Between index hospitalization and discharge, those patients had better treatment outcomes than the patients with long DUP. Moreover, the outcomes were stable over time and better at the 3-, 7- and 12-year follow-ups. The effect proved statistically significant – the analysis of simple effects showed that patients with short DUP had significantly lower results than the patients with long DUP at each measurement point except for the first in-patient hospitalisation (ps: 0.449, 0.002, 0.012, 0.034 and 0.014, respectively).

The results for the positive syndrome were similar to those for general psychopathology. The reduction of positive symptoms was greater in patients with short DPU (Figure 6).

In contrast with the overall PBRS result, at the 7-year follow-up the difference between the 2 groups was not statistically significant (p for all the simple effects measuring the differences between the group at particular follow-up points was 0.230; <0.001, 0.011; 0.214; < 0.001, respectively).

Discussion

Our findings confirm the predictive value of the DUP for the course of schizophrenia, as measured by number of relapses, duration of readmissions, and severity of general and positive symptoms.

One noteworthy finding is the long-term improvement in positive symptoms, assessed by means of the BPRS scale. This improvement was more noticeable in patients characterised by a short duration of untreated psychosis. The symptom improvement was long-lasting, not only between intake and discharge from the ward, but also at all the follow-up points (3-, 7- and 12-year). Bottlender et al. obtained similar results for a 15-year follow-up period – longer DUP involved more intense negative and positive symptoms and general psychopathology, as well as more impaired functioning overall [14]. Assessment over shorter follow-up periods yielded comparable findings. Barnes et al., with a 1-year follow-up period, corroborated the correlation between the longer DUP and severity of positive and negative symptoms and social functioning. Moreover, this finding did not depend on the age of the patients, the severity of their symptoms or their level of social functioning at the beginning of treatment. The correlation with the negative syndrome, which was not present in the Cracovian study, should probably be ascribed to the shortness of the follow-up period when this syndrome is noticeably dynamic [16]. Similarly, Schimmelmann, in his study of 636 patients, incorporating an 18-month follow-up period, found that longer DUP was connected with weaker remission of positive symptoms, a more serious course of schizophrenia, and poorer general functioning both before the onset of the illness and later [17]. The comprehensive meta-analysis by Perkins et al., evaluating 43 publications devoted to the DUP, demonstrated that the findings indicate that a shorter duration of untreated psychosis was connected with symptom improvement in terms of measured general psychopathology, positive and negative symptoms, and functioning [10].

Our study did not produce any results to confirm a correlation between DUP and the dynamics of the negative syndrome. Likewise, studies published worldwide do not report a correlation between the DUP and neuro-cognitive functions or changes in the morphology of the brain [10,24]; yet the negative syndrome is frequently correlated with these variables [18]. The absence of such correlations suggests that the DUP is a more modifiable factor of the illness. Moreover, relapses are regarded as dependent not only on the developing illness but also on environmental factors [19]. The risk of relapse after the first psychotic episode is very high – according to Perkins, as many as 90% of patients experience a relapse during the years immediately following the first episode [10]. In our study, the increment of the number of relapses at subsequent follow-up points was higher in patients who had a long DUP. Nevertheless, the correlation between the number of relapses and the longer DUP proved to be statistically significant only at the 7-year follow-up point (K7). The ambiguous result in relation to the 12-year period may correspond with the divergences encountered by other researchers. De Haan et al discovered a statistically significant correlation between DUP and the risk of relapse, which was confirmed by an assessment after 2 years [25]. Wiersma et al., investigating a 15-year period, as well as Robinson et al., did not encounter any correlations between the duration of untreated psychosis and relapses [13,23].

Despite the lack of statistically significant correlations between DUP and the number and duration of readmissions, a higher increment in number and duration of readmissions can be observed in patients who had a longer DUP. The literature on the subject relates longer duration of untreated psychosis to a variously defined more severe course of schizophrenia [10]. Both relapses and number and duration of readmissions can be considered indicators of this severity. All these indicators are connected with other factors, both biological and environmental, which complicates research on the “pure” impact of the DUP, and requires an extremely critical approach. At the same time, any attempts to control the described variables may bring up ethical considerations.

This article focuses on clinical findings. Internationally, a great deal of research has proven a correlation between DUP and social factors, such as prodromal functioning, employment, social network, and dependence on familial relations, especially the intensity of expressed criticism [11,12,26]. The observed interactions could be more thoroughly understood if a broad spectrum of such factors was examined.

References

1. Häfner H: Risk and Protective Factors in Schizophrenia, 2002, Darmstadt, Steinkopff Verlag

2. Crow TJ, MacMillan JF, Johnson AL, Johnstone EC, A randomised controlled trial of prophylactic neuroleptic treatment: Br J Psychiatry, 1986; 148; 120-27, pmid: 2870753

3. Klosterkoetter J, Predicting the onset of schizophrenia: Risk and Protective Factors in Schizophrenia, 2002; 193-207, Darmstadt, Steinkopff Verlag

4. Häfner H, Onset and early course as determinant of the further course of schizophrenia: Acta Psychiatr Scand, 2000; 102(Suppl 407); 44-48, pmid: 10892609

5. Fariis S, Larsen TK, Melle I, Methodological pitfalls in early detection studies – the NAPE Lecture 2002: Acta Psychiatr Scand, 2003; 107; 3-9, pmid: 12558535

6. Wunderink A, Nienhujs NJ, Sytema S, Wiersma D, Treatment delay and response rate in first episode psychosis: Acta Psychiatr Scand, 2006; 113; 332-39, pmid: 16638078

7. McGlashan TH, Duration of untreated psychosis in first episode schizophrenia: marker or determinant of course?: Biol Psychiatry, 1999; 46; 899-907, pmid: 10509173

8. Norman RM, Malla AK, Duration of untreated psychosis: a critical examination of the concept and its importance: Psychol Med, 2001; 31; 381-400, pmid: 11305847

9. Norman RM, Malla AK, Verdi MB, Understanding delay in treatment for first episode psychosis: Psychol Med, 2004; 34; 255-66, pmid: 14982131

10. Perkins DO, Gu H, Boteva K, Lieberman JA, Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis: Am J Psychiatry, 2005; 162(10); 1785-804, pmid: 16199825

11. Johannessen JO, Larsen TK, McGlashan T, Duration of untreated psychosis: An important target for intervention in schizophrenia: Nord J Psychiatry, 1999; 53(4); 275-83

12. Kalla O, Aaltonen J, Wahlstrom J, Duration of untreated psychosis and its correlates in first-episode psychosis in Finland and Spain: Acta Psychiatr Scand, 2002; 106; 265-75, pmid: 12225493

13. Wiersma D, Nienhuis FJ, Sloff CJ, Giel R, Natural course of schizophrenic disorders: a 15-year follow-up of a Dutch incidence cohort: Schizophr Bull, 1998; 24; 75-85, pmid: 9502547

14. Bottlender R, Sato T, Jager M, The impact of the duration of untreated psychosis prior to first psychiatric admission on the 15-year outcome in schizophrenia: Schizophr Res, 2003; 62; 37-44, pmid: 12765741

15. Alanen YO, Räkköläinen V, Rasimus R, Psychotherapeutically oriented treatment of schizophrenia: Results of 5-year follow-up: Acta Psychiatrica Scandinavica, 1985; 71(319); 31-49, pmid: 3863459

16. Barnes TRE, Leeson VC, Mutsatsa SH, Duration of untreated psychosis and social function: 1-year follow-up study of first-episode schizophrenia: Br J Psychiatry, 2008; 193; 2003-9

17. Schimmelmann BG, Huber ChG, Lambert M, Impact of duration of untreated psychosis on pre-treatment, baseline, and outcome characteristics in an epidemiological first-episode psychosis cohort: J Psychiatr Res, 2008; 42; 982-90, pmid: 18199456

18. Mosiołek A, Łoza B, Co mierzą testy neurokognitywne w schizofrenii?: Via Medica, 2004; 1(2); 113-19 [in Polish]

19. Cechnicki A, Prospektywne badania przebiegu schizofrenii – nawrót i rehospitalizacja jako kryterium wyników leczenia: Postępy Psychiatrii i Neurologii, 1997; 5(Suppl 2); 7-15 [in Polish]

20. Perkins D, Liebermann JA, Gu H, Predictors of antipsychotic treatment response in patients with firs-episode schizophrenia, schizoaffective and schizophreniform disorders: Br J Psychiatry, 2004; 185; 18-24, pmid: 15231551

21. Peralta V, Cuesta M, Martinez-Larrea JA, Duration of untreated psychotic illness. The role of premorbid social support networks: Soc Psychiatry, Psychiatry Epidemiol, 2005; 40; 345-49

22. Wciórka J, Kryteria diagnostyczne według DSM IV-TR: Wyd: Amerykańskie Towarzystwo Psychiatryczne, 2008, Arlington VA, Wrocław Qick reference to the diagnostic criteria from DSM IV-TR Polish edition Elsevier Urban&Partner

23. Robinson D, Werner MG, Alvir JM, Predictors relapse following response from a first episode of schizophrenia or schizoaffective disorder: Arch Gen Psychiatry, 1999; 56; 241-47, pmid: 10078501

24. Galińska B, Szulc A, Tarasow E, Duration of untreated psychosisi and proton magnetic resonance spectroscopy (1H-MRS) findings in first episode schizophrenia: Med Sci Monit, 2009; 15(2); CR82-88, pmid: 19179972

25. De Haan L, Linszen DH, Lenior MEI, Duration of untreated psychosis and outcome of schizophrenia: Delay in intensive psychosocial treatment versus delay in treatment with antipsychotic medication: Schizophr Bull, 2003; 29; 341-49, pmid: 14552508

26. Compton MT, Chien VH, Leiner AS, Mode of onset of psychosis and family involvement in help-seeking as determinants of duration of untreated psychosis: Soc Psychiatry Psychiatr Epidemiol, 2008; 43; 975-82, pmid: 18604616

In Press

Clinical Research  

Institutional and Regional Variations in Access to Clinical Trials and Next-Generation Sequencing in Turkis...

Med Sci Monit In Press; DOI: 10.12659/MSM.951027  

Clinical Research  

Low-Intensity Blood Flow-Restricted Multi-Joint Exercise Improves Muscle Function in Patients With Patellof...

Med Sci Monit In Press; DOI: 10.12659/MSM.950516  

Review article  

Musculoskeletal Ultrasound and MRI in the Evaluation of Chemotherapy-Induced Peripheral Neuropathy: A Review

Med Sci Monit In Press; DOI: 10.12659/MSM.951283  

Clinical Research  

Sensory Processing, Dissociation, and Affective Symptoms in Misophonia: A Cross-Sectional Study of 35 Adults

Med Sci Monit In Press; DOI: 10.12659/MSM.950938  

Most Viewed Current Articles

17 Jan 2024 : Review article   10,187,196

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

13 Nov 2021 : Clinical Research   3,708,487

Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...

DOI :10.12659/MSM.932788

Med Sci Monit 2021; 27:e932788

0:00

14 Dec 2022 : Clinical Research   2,341,643

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

16 May 2023 : Clinical Research   706,524

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750